Case Reports in Oncology Case Rep Oncol 2022;15:388–393 DOI: 10.1159/000523989 Received: February 3, 2022

© 2022 The Author(s). Published by S. Karger AG, Basel www.karger.com/cro OPEN ACCESS

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

Case Report

Poorly Differentiated Neuroendocrine Carcinoma of Unknown Primary with Metastasis to the Testis: A Case Report

Accepted: March 1, 2022

Published online: April 8, 2022

Momoko Sano^a Masaaki Noguchi^a Akiyoshi Kinoshita^a Mayo Nakamura^b Kazuhiko Koike^a Masayuki Saruta^c

^aDivision of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, Tokyo, Japan; ^bDivision of Pathology, The Jikei University Daisan Hospital, Tokyo, Japan; ^cDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

Keywords

Neuroendocrine carcinoma · Neuroendocrine tumors · Testis · Unknown primary neoplasms

Abstract

Neuroendocrine neoplasms are rare epithelial neoplasms with neuroendocrine differentiation. Few cases of primary testicular poorly differentiated neuroendocrine carcinomas (PD-NECs) have been reported, and secondary testicular neoplasms are rare. A 61-year-old man with a chief complaint of left testicular swelling was referred to our hospital. An orchiectomy was performed in order to determine the pathological diagnosis. Pathological examination showed diffuse sheets of highly atypical cells that were positive for neuroendocrine markers and a Ki-67 proliferation index of 80%. The patient was diagnosed with poorly differentiated small-cell NEC. Contrast-enhanced computed tomography revealed multiple metastases to the pancreas, adrenal glands, and lymph nodes. Esophagogastroduodenoscopy showed multiple gastric metastases, and biopsy revealed the same histological findings as observed for the testicular tumor. Contrast-enhanced magnetic resonance imaging of the head also revealed multiple brain metastases. The confirmed diagnosis was PD-NEC of unknown primary with metastases to the testis, stomach, pancreas, adrenal glands, brain, and lymph nodes. We started the first-line chemotherapy with etoposide and cisplatin. Stereotactic radiotherapy for the brain metastases was administered between the first and second cycles. After five cycles, a partial response was observed; however, disease progression was observed after seven cycles with recurrence of the brain metastases and enlargement of all tumors. To our knowledge, this is the first report of an unknown primary PD-NEC with metastasis to the testis.

> © 2022 The Author(s). Published by S. Karger AG, Basel

Correspondence to: Masaaki Noguchi, masaaki.noguchi1983@gmail.com



Ca	se	Reports
in	On	cology

DOI: 10.1159/000523989	© 2022 The Author(s). Published by S. Karger AG, Basel

Sano et al.: Neuroendocrine Carcinoma of Unknown Primary with Metastasis to the Testis

Introduction

Neuroendocrine neoplasms (NENs) are rare epithelial neoplasms with morphological and immunohistochemical features of neuroendocrine differentiation [1, 2]. The annual age adjusted incidence of NENs is 6.98 per 100,000 [1]. The WHO Classification of Digestive System Tumours published in 2019 classified NENs as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (PD-NECs). NETs are well differentiated and graded as low grade, intermediate grade, and high grade, depending on the mitotic rate and the Ki-67 proliferation index. In contrast, PD-NECs are poorly differentiated and high-grade, with a mitotic rate of >20 mitoses/2 mm² and a Ki-67 proliferation index of >20%. Moreover, they are classified as neuroendocrine carcinoma small- or large-cell types [2]. PD-NECs were not distinguished from NETs clearly before the revision of the WHO classification in 2019. Thus, NETs were often reported as PD-NECs in many papers and vice versa.

While cases of primary testicular NETs have been reported, primary testicular PD-NECs have rarely been observed [3]. Secondary testicular neoplasms are also rare [4]. Here, we report a rare case of an unknown primary PD-NEC with metastasis to the testis, which was diagnosed with orchiectomy.

Case Report/Case Presentation

A 61-year-old man with a chief complaint of left testicular swelling was referred to our hospital in 2020. He had hypertension, for which he had taken calcium channel blockers and angiotensin II receptor blockers, and no previous skin cancer history. The patient had no family history. Physical examination revealed swelling of the left testis. Ultrasonography of the left testis showed lower luminant mass which was heterogeneous in echo texture and had blood flow inside. Contrast-enhanced computed tomography revealed multiple pancreatic tumors with dilation of the main pancreatic duct, bilateral adrenal tumors, right axillary lymph node enlargement, and multiple abdominal lymph nodes enlargement (shown in Fig. 1). No significant lesion was observed in the lung field. The levels of human chorionic gonadotropin and β -human chorionic gonadotropin were normal. A primary testicular tumor with metastases to the pancreas, adrenal glands, and lymph nodes was suspected. An orchiectomy was performed in order to determine the pathological diagnosis. Macroscopically, the resected left testis measured 46 × 40 × 32 mm. The cut surface showed a white solid tumor with bleeding and necrosis (shown in Fig. 2a). Pathological examination showed diffuse sheets of highly atypical cells with scant



Fig. 1. Multiple tumors (arrow) of the head, body (**a**), and tail (**b**) of the pancreas on contrast-enhanced CT. CT, computed tomography.



Case Reports in Oncology

Case Rep Oncol 2022;15:388–393
DOI: 10.1159/000523989
© 2022 The Author(s). Published by S. Karger AG, Basel
www.karger.com/cro

Sano et al.: Neuroendocrine Carcinoma of Unknown Primary with Metastasis to the Testis



Fig. 2. Pathological specimen of the left testis. **a** The resected left testis, measuring 46 × 40 × 32 mm, with the cut surface of the white solid tumor with bleeding and necrosis. **b** Histological findings with H&E staining show diffuse sheets of highly atypical cells with scant cytoplasm and irregularly fusiform nuclei with granular chromatin. Several mitoses are visible. **c** Immunohistochemistry shows labeling for synaptophysin (**c**1), chromogranin A (**c**2), CD56 (**c**3), and TTF1 (**c**4). **d** A Ki-67 proliferation index with MIB-1 stain of 80%. **e** An isochromosome of the short arm of chromosome 12 (i12p) is not apparent by FISH (green signal). The i12p/ CEP12 ratio was 104/92 (<1.5). TTF1, thyroid transcription factor-1. H&E, hematoxylin and eosin.

cytoplasm and irregularly fusiform nuclei with granular chromatin. Mitoses and apoptosis were observed remarkably (shown in Fig. 2b). In immunohistochemistry, these atypical cells were positive for synaptophysin (shown in Fig. 2c1), chromogranin A (shown in Fig. 2c2), CD56 (shown in Fig. 2c3), and thyroid transcription factor-1 (shown in Fig. 2c4), and the Ki-67 proliferation index was 80% (shown in Fig. 2d). The seminiferous tubules around the tumor were negative for SALL4 and Oct3/4 which indicate the presence of germ cell neoplasia in situ immunohistochemically. These atypical cells did not show isochromosomes of the short arm of chromosome 12 (i12p) in fluorescence in situ hybridization (FISH) (shown in Fig. 2e). According to the WHO Classification of Digestive System Tumours in 2019, we diagnosed the tumor as poorly differentiated small-cell NEC [2].

The levels of serum tumor markers were elevated with CEA of 28.7 ng/mL, NSE of 43.9 ng/mL, and ProGRP of 257 pg/mL. Esophagogastroduodenoscopy showed multiple gastric metastases resembling a submucosal tumor in the gastric body (Fig. 3a). The biopsy revealed the same histological findings as those for the testicular tumor. No abnormalities were found in colonoscopy. Contrast-enhanced magnetic resonance imaging of the head revealed multiple brain metastases (Fig. 3b). The confirmed diagnosis was PD-NEC of unknown primary, with metastases to the testis, stomach, pancreas, adrenal glands, brain, and lymph nodes.



Case Reports in Oncology	Case Rep Oncol 2022;15:388–393		391	
	DOI: 10.1159/000523989	© 2022 The Author(s). Published by S. Karger AG, Basel www.karger.com/cro		
	Sano et al.: Neuroendocrine Carcinoma of Unknown Primary with Metastasis to the Testis			



Fig. 3. Multiple metastases. **a** EGDS shows multiple gastric metastases (arrow) resembling submucosal tumors in the gastric body. **b** Contrast-enhanced MRI of the head shows multiple brain metastases (arrow). EGDS, esophagogastroduodenoscopy; MRI, magnetic resonance imaging.

Chemotherapy with etoposide (100 mg/m²) and cisplatin (80 mg/m²) was administered as the first-line chemotherapy in combination with pegfilgrastim. Stereotactic radiotherapy for the brain metastases was performed between the first and second cycles. After five cycles of chemotherapy, the sum of diameters of the target lesions decreased from 142 mm to 74 mm, and a partial response was achieved according to RECIST guideline version 1.1 [5]. Disease progression was observed after seven cycles of chemotherapy, with a chief complaint of appetite loss and fatigue. Magnetic resonance imaging of the head showed recurrence of the brain metastases, and computed tomography revealed enlargement of all tumors. After the whole-brain irradiation, the second-line chemotherapy with ramucirumab and paclitaxel was performed. After seven cycles, disease progression was observed with the enlargement of all tumors. Although only one cycle of third-line chemotherapy with nivolumab was performed, the chemotherapy was discontinued due to his poor performance status. He died 15 months after the diagnosis while receiving palliative care.

Discussion/Conclusion

NENs arise from enterochromaffin cells, which are distributed in most epithelial organs of the body, including the lungs, digestive tracts, pancreas, thyroid, adrenal glands, and other organs [2]. The most common primary sites of NENs are the respiratory and gastrointestinal tracts. NENs are rarely observed in the testis, which is not an epithelial organ [1]. In immunohistochemistry, NENs are positive for neuroendocrine markers of synaptophysin, chromogranin A, and CD56 [2]. In addition, TTF-1 appears on not only pulmonary NECs but also extrapulmonary NECs; for example, those arising in the digestive and urogenital systems [6].

However, there have been several reports on testicular NENs. NENs arising from the testis are thought to occur in the background of teratomas because testicular NENs have i12p, which is the most common chromosomal abnormality occurring in germ cell tumors [7]. In our case, the testicular tumor did not coexist with teratomas or germ cell neoplasia in situ which represents the precursor lesions for many types of testicular germ cell tumors. In addition, FISH did not detect i12p. Although we cannot completely deny the diagnosis of a primary testicular tumor, these findings suggest that this testicular tumor did not occur in the background of teratomas.

Karger

Case Rep Oncol 2022;15:388–39	3
DOI: 10.1159/000523989	© 2022 The Author(s). Published by S. Karger

Case Reports AG, Basel www.karger.com/cro in Oncology Sano et al.: Neuroendocrine Carcinoma of Unknown Primary with Metastasis to the Testis

Although several cases of testicular NENs have been observed, few cases of primary testicular NECs have been reported. One Croatian urologist reported a case of primary testicular largecell neuroendocrine carcinoma with metastases to the inguinal lymph nodes [8]. In a comparative study of lung and extrapulmonary PD-NEC based on the SEER database including 162,983 cases of PD-NEC, only 9 cases (0.0055%) originated in the male genital tract except for the prostate; however, 4,151 cases (2.8%) were unknown [9]. As for germ cell tumors, most testicular germ cell tumors metastasize to the lung, liver, bone, and brain; furthermore, only one case of testicular germ cell tumor with gastric metastasis has been reported [10, 11]. In our case, since the gastric tumors were multiple and submucosal-like, we diagnosed them as metastatic tumors in the stomach [12]. In addition, the pancreatic tumors were also assessed to be secondary pancreatic tumors because these were multinodular lesions with fusion [13]. Therefore, we concluded that this case was an unknown primary PD-NEC with multiple organ metastases including the testis, rather than a primary testicular PD-NEC.

Metastases to the testis, stomach, and pancreas from solid tumors are rare. A retrospective study of 738 consecutive autopsies of adult men with solid malignant neoplasms reported only 5 cases (0.68%) of secondary testicular neoplasms [4]. In another study of 6,380 autopsied patients with solid malignant neoplasms, 347 cases (5.4%) had metastases to the stomach [14]. Moreover, in another autopsy study of 690 cases of malignant tumors, 103 cases (14.9%) had pancreatic secondary tumors [15]. In contrast, metastases from small-cell lung carcinoma and gastrointestinal NEC have often been found in the liver, bone, lung, and brain [16, 17]. Based on these studies, metastases to the testis, stomach, and pancreas are very rare for solid tumors, including NECs.

In summary, our case was an unknown primary PD-NEC rather than a primary testicular PD-NEC. Furthermore, PD-NECs rarely metastasize to the testis. To our knowledge, this is the first report of an unknown primary PD-NEC with metastasis to the testis diagnosed according to the recent classification of NENs.

Acknowledgment

We would like to express our gratitude to Ms. Reiko Watanabe from the National Cancer Center Hospital East and Mr. Kosuke Miyai from National Defense Medical College for their help with pathological diagnosis, including FISH and immunohistochemistry.

Statement of Ethics

Written informed consent was obtained from the patient's next of kin for publication of the details of their medical case and any accompanying images. Ethical approval was not required for this study in accordance with local guidelines.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

No funding was received.



Case Rep Oncol 2022	;15:388–393
---------------------	-------------

Case Reports in Oncology

OOI: 10.1159/000523989 © 2022 The Author(s). Published by S. Karger AG, Basel www.karger.com/cro www.karger.com/cro			
	OOI: 10.1159/000523989	© 2022 The Author(s). Published by S. Karger AG, Basel www.karger.com/cro	

Sano et al.: Neuroendocrine Carcinoma of Unknown Primary with Metastasis to the Testis

Author Contributions

Momoko Sano is the lead author. Masaaki Noguchi is a guarantor of integrity of the entire study. Momoko Sano and Masaaki Noguchi carried out literature research and manuscript preparation. Momoko Sano, Masaaki Noguchi, Akiyoshi Kinoshita, Mayo Nakamura, Kazuhiko Koike, and Masayuki Saruta were involved in manuscript editing.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

References

- 1 Dasari A, Shen C, Halperin D, Bo Z, Shouhao Z, Ying X, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017 Oct;3(10):1335–42.
- 2 WHO Classification of Tumours Editorial Board. WHO classification of tumours. In: Digestive system tumours. 5th ed. Lyon, France: World Health Organization; 2019.
- 3 Amine MM, Mohamed B, Mourad H, Majed H, Slim C, Mehdi B, et al. Neuroendocrine testicular tumors: a systematic review and meta-analysis. Curr Urol. 2016 Jul;10(1):15–25.
- 4 García-González R, Pinto J, Val-Bernal JF. Testicular metastases from solid tumors: an Autopsy Study. Ann Diagn Pathol. 2000 Apr;4(2):59–64.
- 5 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228–47.
- 6 La Rosa S, Chiaravalli AM, Placidi C, Papanikolaou N, Cerati M, Capella C. TTF1 expression in normal lung neuroendocrine cells and related tumors: Immunohistochemical Study comparing two different monoclonal antibodies. Virchows Arch. 2010 Oct;457(4):497–507.
- 7 Abbosh PH, Zhang S, MacLennan GT, Montironi R, Lopez-Beltran A, Rank JP, et al. Germ cell origin of testicular carcinoid tumors. Clin Cancer Res. 2008 Mar;14(5):1393–6.
- 8 Maričić A, Katunarić M, Šutalo N, Tomic S, Jurisic D, Petkovic M, et al. Primary large-cell neuroendocrine carcinoma of the scrotum. Wien Klin Wochenschr. 2010 Jun;122(11–12):360–2.
- 9 Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative Study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer. 2018 Feb;124(4): 807–15.
- 10 Harikumar R, Harish K, Aravindan KP, Thomas V. Testicular choriocarcinoma with gastric metastasis presenting as hematemesis. Indian J Gastroenterol. 2004 Nov;23(6):223–4.
- 11 International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997 Feb;15(2):594–603.
- 12 Kim GH, Ahn JY, Jung HY, Park YS, Kim MJ, Choi KD, et al. Clinical and endoscopic features of metastatic tumors in the stomach. Gut Liver. 2015 Sep;9(5):615–22.
- 13 Ferrozzi F, Bova D, Campodonico F, Chiara FD, Passari A, Bassi P. Pancreatic metastases: CT assessment. Eur Radiol. 1997;7(2):241–5.
- 14 Oda I, Kondo H, Yamao T, Saito D, Ono H, Gotoda T, et al. Metastatic tumors to the stomach: analysis of 54 patients diagnosed at endoscopy and 347 autopsy cases. Endoscopy. 2001 Jun;33(6):507–10.
- 15 Nakamura E, Shimizu M, Itoh T, Manabe T. Secondary tumors of the pancreas: Clinicopathological Study of 103 autopsy cases of Japanese patients. Pathol Int. 2001 Sep;51(9):686–90.
- 16 Megyesfalvi Z, Tallosy B, Pipek O, Fillinger J, Lang C, Klikovits T, et al. The landscape of small cell lung cancer metastases: organ specificity and timing. Thorac Cancer. 2021 Mar;12(6):914–23.
- 17 Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, et al. High-grade gastrointestinal neuroendocrine carcinoma management and outcomes: a National Cancer Database Study. Oncologist. 2019 Jul;24(7):911–20.

